Conditions: Retinal Vein Occlusion Age Related Macular Degeneration
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: no

Brief summary:
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion and age-related macular degeneration.

Currently, there is limited epidemiologic information in Chile regarding the incidence of DME and limited experience of anti-VEGF hospital therapy. This study will evaluate the efficacy of intravitreal ranibizumab in Chilean DME patients, to investigate the anatomical and functional improvement following this treatment and to increase the local experience regarding the use of anti-VEGF in the treatment of diabetic macular edema.

Detailed description:

Arms:
arm 1: Ranibizumab treatment

Interventions: intervention 1: Ranibizumab Intravitreal injections
Intervention descriptions: intervention 1: Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.

Protocol document: